Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Anal squamous cell carcinoma (ASCC) is a human papillomavirus (HPV)-driven malignancy with limited therapeutic advancements over four decades.
• Treatment options for recurrent ASCC, particularly when surgery is not feasible, remain inadequate.
• Existing research on tumor suppressor genes and targeted pathways has not yielded clinically useful biomarkers.

Purpose of the Study:

• To review the molecular biology of ASCC.
• To discuss ongoing clinical trials and identify novel therapeutic targets.
• To highlight the need for improved preclinical models for ASCC research.

Main Methods:

• Literature review of molecular pathways, targeted therapies, and clinical trials in ASCC.
• Analysis of the role of HPV in immune evasion and disease progression.
• Discussion of potential therapeutic strategies including immunotherapy and targeted agents.

Main Results:

• HPV evasion of the immune system presents opportunities for immunotherapy.
• Targeting apoptosis regulators (e.g., survivin) and the PI3K/AKT pathway shows therapeutic potential, though data are limited.
• EGFR antibody therapy's safety in combination regimens requires further investigation.

Conclusions:

• Progress in ASCC treatment is hindered by a lack of robust preclinical models.
• Future research should prioritize developing and utilizing preclinical models to investigate new molecular pathways and test novel therapeutic targets.
• Exploiting HPV's immune evasion mechanisms and targeting specific molecular pathways are key avenues for future ASCC therapies.